Unicycive Therapeutics Stock (NASDAQ:UNCY)

Forecast Ownership Financials Chart

Previous Close

$5.13

52W Range

$3.71 - $11.00

50D Avg

$4.37

200D Avg

$5.40

Market Cap

$92.55M

Avg Vol (3M)

$429.67K

Beta

1.86

Div Yield

-

UNCY Company Profile

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

22

IPO Date

Jul 12, 2021

Website

UNCY Performance

UNCY Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	-	$675.00K	$951.00K
Operating Income	$-32.12M	$-20.77M	$-18.05M
Net Income	$-37.82M	$-30.54M	$-18.06M
EBITDA	$-32.12M	$-30.18M	$-18.05M
Basic EPS	$-0.06	$-1.28	$-1.20
Diluted EPS	$-0.06	$-1.28	$-1.20

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

Ticker	Company
IMA	ImageneBio Inc
HYFT	MindWalk Holdings Corp.
IFRX	InflaRx N.V.
RPTX	Repare Therapeutics Inc.
FBIO	Fortress Biotech, Inc.
NTRB	Nutriband Inc.
IMUX	Immunic, Inc.
VXRT	Vaxart, Inc.
STTK	Shattuck Labs, Inc.